Our data are consistent with prior studies in erlotinib resistant NSCLC cells [10] as well as studies in breast cancer cells demonstrating that the EMT phenotype is close associated with Axl overexpression [38]. This evidence concerns the gene AXL and non-small cell lung carcinoma.